Insider trading · Q3 2026 · CIK 1439222

Agios Pharmaceuticals, Inc. (AGIO) insider trading.

In Q3 2026, insiders at Agios Pharmaceuticals, Inc. reported 4 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $1.1M.

Transactions
4
Purchases (P)
0
Sales (S)
2
Net shares, P minus S
-34,007
Insiders
2
Last filed
2026-08-06

Insiders

InsiderRelationshipTransactionsBuysSales
Gheuens SarahOfficer · Chief Medical Officer302
Backstrom Jay T.Director100

Transactions

4 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-08-04Gheuens SarahS (D)30,000$30.4854,645Form 4
2026-07-08Backstrom Jay T.A (A)1,447$01,447Form 4
2026-07-01Gheuens SarahM (A)8,375$088,652Form 4
2026-07-01Gheuens SarahS (D)4,007$37.5684,645Form 4

Transaction codes in this quarter

Get AGIO insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1439222&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · AGIO company page · Agios Pharmaceuticals, Inc. on SEC.gov

Questions

Are insiders buying or selling Agios Pharmaceuticals, Inc. (AGIO)?

In Q3 2026, insiders at Agios Pharmaceuticals, Inc. reported 4 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $1.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Agios Pharmaceuticals, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/agio.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.